

Therapeutic subgroup (ATC level 2)	No harm	Low harm	Moderate harm	Severe harm	Death	Total medication errors (n)	Total medication errors (%)
<b>Analgesics (N02)</b>	158	222	77	19	7	485	14.3
<b>Antibacterials for systemic use (J01)</b>	207	166	51	19	3	458	13.5
<b>Antithrombotic agents (B01)</b>	164	113	56	44	6	398	11.8
<b>I.V. Solutions (not an ATC category)</b>	84	88	51	8	0	238	7.2
<b>Psycholeptics (N05)</b>	71	73	26	12	2	190	5.7
<b>Antineoplastic agents and immunomodulating agents (L01-L04)</b>	64	59	38	14	2	183	5.5
<b>Drugs used in diabetes (A10)</b>	57	83	29	8	0	182	5.4
<b>Antihypertensives and Beta blocking agents (C02 and C07)</b>	64	70	22	5	0	161	4.8
<b>Cardiac therapy (C01)</b>	50	45	35	9	2	141	4.2
<b>Other</b>	59	45	22	9	0	137	4.1
<b>Corticosteroids for systemic use (H02)</b>	34	34	15	2	0	85	2.5
<b>Anesthetics (N01)</b>	20	26	17	6	1	70	2.1
<b>Antiepileptics (N03)</b>	21	29	8	2	0	62	1.8
<b>Diagnostic agents (V04)</b>	7	22	14	4	0	47	1.4
<b>Diuretics (C03)</b>	13	21	8	2	2	47	1.4
<b>Psychoanaleptics (N06)</b>	16	14	7	1	0	38	1.1
<b>Other nervous system drugs (N07)</b>	13	15	4	1	2	36	1.1
<b>Drugs for functional gastrointestinal disorders (A03)</b>	11	11	9	0	0	32	0.9
<b>Vitamins and Mineral supplements (A11 and A12)</b>	12	13	2	1	0	29	0.9
<b>Drugs for Treatment of Bone Diseases (M05)</b>	8	3	3	1	0	15	0.4
<b>Drugs for obstructive airway diseases (R03)</b>	1	8	4	0	0	13	0.4
<b>Muscle relaxants (M03)</b>	4	3	3	2	0	12	0.4
<b>Lipid modifying agents (C10)</b>	7	4	0	0	0	11	0.3
<b>Sex hormones and modulators of the genital system (G03)</b>	3	2	3	2	0	10	0.3
<b>Antihemorrhagics (B02)</b>	4	2	2	0	0	9	0.2
<b>Immune sera and Immunoglobulins (J06)</b>	2	1	3	1	0	8	0.2
<b>All other therapeutic agents (V03)</b>	3	3	0	0	0	6	0.2
<b>Missing</b>	N/A	N/A	N/A	N/A	N/A	269	7.9
<b>Total</b>	1157	1175	509	172	27	3372	100

**Appendix B** Characteristics of the most commonly reported therapeutic subgroups in relation to the degree of harm reported to the Norwegian Incident Reporting System (NIRS) in 2016 and 2017